Page last updated: 2024-11-04

rofecoxib and Premature Rupture of Fetal Membranes

rofecoxib has been researched along with Premature Rupture of Fetal Membranes in 1 studies

Research Excerpts

ExcerptRelevanceReference
"Rofecoxib has a significant but reversible effect on fetal renal function and the ductus arteriosus."2.71TOCOX--a randomised, double-blind, placebo-controlled trial of rofecoxib (a COX-2-specific prostaglandin inhibitor) for the prevention of preterm delivery in women at high risk. ( Bennett, PR; Groom, KM; Jones, BA; Seed, P; Shennan, AH, 2005)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Groom, KM1
Shennan, AH1
Jones, BA1
Seed, P1
Bennett, PR1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Clinical Trial of a COX-2 Inhibitor for the Treatment of Women With Preeclampsia[NCT00442676]Phase 20 participants (Actual)Interventional2009-06-30Withdrawn (stopped due to No patients were recruited. Treatment drug expired.)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trials

1 trial available for rofecoxib and Premature Rupture of Fetal Membranes

ArticleYear
TOCOX--a randomised, double-blind, placebo-controlled trial of rofecoxib (a COX-2-specific prostaglandin inhibitor) for the prevention of preterm delivery in women at high risk.
    BJOG : an international journal of obstetrics and gynaecology, 2005, Volume: 112, Issue:6

    Topics: Adult; Blood Flow Velocity; Cyclooxygenase Inhibitors; Double-Blind Method; Ductus Arteriosus; Femal

2005